{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113520","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2024-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.087875+00:00","generated_at":"2026-05-30T18:04:32.402594+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Cue Biopharma stockholders approve doubling authorized common stock to 200M shares","bullets":["Authorized shares increased from 110M to 210M total, common from 100M to 200M.","Shareholders voted 29,291,818 for, 7,409,258 against, 499,006 abstain at Oct 8, 2024 special meeting.","Certificate of Amendment filed with Delaware Secretary of State on October 8, 2024.","No specific issuance plan disclosed; amendment provides flexibility for future capital needs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113520","json":"https://secwatch.observer/filing/0000950170-24-113520.json","markdown":"https://secwatch.observer/filing/0000950170-24-113520.md","text":"https://secwatch.observer/filing/0000950170-24-113520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024113520/0000950170-24-113520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024113520/cue-20241008.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T18:04:32.402594+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb1c56fa7c58e7511c0d63835d784c4edf04b91d","claim":"Cue Biopharma, Inc.: Increased authorized shares of capital stock from 110,000,000 to 210,000,000 and authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2024-10-08).","evidence_excerpt":"On October 8, 2024, Cue Biopharma, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware effecting an amendment to increase the number of authorized shares of the Company’s capital stock from 110,000,000 to 210,000,000 and increase the number of authorized shares of the Company’s common stock from 100,000,000 to 200,000,000.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000095017024113520/0000950170-24-113520-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-10-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}